• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

    7/24/24 5:27:11 AM ET
    $ALLR
    $ATCH
    $ATIP
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $ALLR alert in real time by email

    Shares of Enphase Energy, Inc. (NASDAQ:ENPH) rose sharply in today's pre-market trading after the company reported second-quarter financial results.

    Enphase Energy reported second-quarter revenue of $303.46 million, missing the consensus estimate of $309.67 million, according to Benzinga Pro. The company reported adjusted earnings of 43 cents per share, missing analyst estimates of 48 cents per share.

    Enphase Energy shares gained 6.2% to $110.10 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 146.2% to $3.20 in pre-market trading after falling over 22% on Tuesday.
    • NuZee, Inc.  (NASDAQ:NUZE) gained 87.4% to $1.93 in pre-market trading.
    • Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares climbed 65.4% to $24.74 in pre-market trading after jumping 344% on Tuesday.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) gained 41.1% to $0.2350 in pre-market trading. Allarity Therapeutics revealed on Monday it received a "Wells Notice" from the U.S. Securities and Exchange Commission (SEC).
    • NewGenIvf Group Limited (NASDAQ:NIVF) shares gained 30.1% to $1.12 in pre-market trading after the company announced steady progress in its due diligence efforts in its proposed reverse merger with COVIRIX Medical and anticipates completion by the end of August 2024.
    • Perfect Moment Ltd.  (NASDAQ:PMNT) gained 19% to $2.20 in pre-market trading after gaining around 9% on Tuesday.
    • ENGlobal Corporation (NASDAQ:ENG) shares gained 15% to $2.00 in pre-market trading.
    • 1847 Holdings LLC (NYSE:EFSH) shares gained 14.4% to $2.30 in pre-market trading after falling over 17% on Tuesday. 1847 Holdings recently announced a 1-for-13 reverse split.
    • Seagate Technology Holdings plc (NASDAQ:STX) shares surged 5.3% to $110.90 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.

    Losers

    • Azitra, Inc. (NYSE:AZTR) shares fell 74.7% to $1.26 in pre-market trading. Azitra announced the pricing of $10.0 million public offering.
    • Conn’s, Inc. (NASDAQ:CONN) shares fell 34.9% to $0.33 in pre-market trading as the company announced plans to close 71 locations across 13 states.
    • Verastem, Inc. (NASDAQ:VSTM) shares fell 27.6% to $2.60 in pre-market trading after the company reported pricing of $55.0 million public offering of common stock, warrants and pre-funded warrants.
    • ATI Physical Therapy, Inc. (NYSE:ATIP) shares declined 25.7% to $4.55 in pre-market trading after gaining around 5% on Tuesday.
    • Volato Group, Inc. (NYSE:SOAR) shares fell 25.2% to $0.4408 in pre-market trading after gaining around 23% on Tuesday.
    • Chijet Motor Company, Inc. (NASDAQ:CJET) fell 21.1% to $4.01 in pre-market trading after jumping 55% on Tuesday.
    • AtlasClear Holdings, Inc. (NASDAQ:ATCH) shares declined 20.6% to $0.44 in pre-market trading after gaining 11% on Tuesday.
    • Wheels Up Experience Inc. (NYSE:UP) fell 9.8% to $3.00 in pre-market trading. Wheels Up Experience will release its second quarter financial results on Thursday, Aug. 8.
    • SFL Corporation Ltd. (NYSE:SFL) shares dipped 9.3% to $12.65 in pre-market trading after the company announced an offering of 8 million common shares.
    • Tesla, Inc. (NASDAQ:TSLA) shares fell 7.2% to $228.56 in pre-market trading. Tesla reported weaker-than-expected earnings for its second quarter, while sales topped estimates. The company reported second-quarter deliveries of 443,956 vehicles and production of 410,831 vehicles, down 5% and 14% year-over-year, respectively.

    Now Read This:

    • Tesla, AT&T And 3 Stocks To Watch Heading Into Wednesday
    Get the next $ALLR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $ATCH
    $ATIP
    $AZTR

    CompanyDatePrice TargetRatingAnalyst
    Enphase Energy Inc.
    $ENPH
    7/30/2025$45.00Buy → Accumulate
    Johnson Rice
    Seagate Technology Holdings PLC
    $STX
    7/30/2025$175.00Neutral → Overweight
    Cantor Fitzgerald
    Seagate Technology Holdings PLC
    $STX
    7/30/2025$135.00 → $175.00Buy
    TD Cowen
    Tesla Inc.
    $TSLA
    7/29/2025$319.00 → $325.00Outperform
    RBC Capital Mkts
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Tesla Inc.
    $TSLA
    7/25/2025$349.00Buy → Hold
    China Renaissance
    Tesla Inc.
    $TSLA
    7/24/2025$303.00 → $333.00Buy
    Canaccord Genuity
    Enphase Energy Inc.
    $ENPH
    7/23/2025$45.00 → $40.00Hold
    TD Cowen
    More analyst ratings

    $ALLR
    $ATCH
    $ATIP
    $AZTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Enphase Energy downgraded by Johnson Rice with a new price target

    Johnson Rice downgraded Enphase Energy from Buy to Accumulate and set a new price target of $45.00

    7/30/25 10:54:27 AM ET
    $ENPH
    Semiconductors
    Technology

    Seagate Tech upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Seagate Tech from Neutral to Overweight and set a new price target of $175.00

    7/30/25 7:19:36 AM ET
    $STX
    Electronic Components
    Technology

    TD Cowen reiterated coverage on Seagate Tech with a new price target

    TD Cowen reiterated coverage of Seagate Tech with a rating of Buy and set a new price target of $175.00 from $135.00 previously

    7/30/25 6:55:45 AM ET
    $STX
    Electronic Components
    Technology

    $ALLR
    $ATCH
    $ATIP
    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Kothandaraman Badrinarayanan bought $154,120 worth of shares (5,000 units at $30.82) (SEC Form 4)

    4 - Enphase Energy, Inc. (0001463101) (Issuer)

    8/6/25 4:56:28 PM ET
    $ENPH
    Semiconductors
    Technology

    Director Gottschalk Max bought $12,933 worth of shares (45,900 units at $0.28), increasing direct ownership by 13% to 52,920 units (SEC Form 4)

    4 - Perfect Moment Ltd. (0001849221) (Issuer)

    7/11/25 5:00:11 PM ET
    $PMNT
    Apparel
    Consumer Discretionary

    Large owner Benaron Reeve bought $300,000 worth of shares (1,000,000 units at $0.30) (SEC Form 4)

    4 - Perfect Moment Ltd. (0001849221) (Issuer)

    7/2/25 6:54:02 PM ET
    $PMNT
    Apparel
    Consumer Discretionary

    $ALLR
    $ATCH
    $ATIP
    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

        - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. "The second quarter of 2025 marked a period

    8/15/25 4:30:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    1847 Holdings Reports 380% Revenue Growth to $12.8 Million in Q2 2025

    Gross Profit Rises 462% to $6.7 Million Net Income from Continuing Operations Improved by $26.6 Million to $23.7 Million Revenue for First Half of 2025 Increased 382% to $22.9 Million, a $18.1 Million Increase from Prior Year Generated $973,606 in Positive Cash Flow from Continuing Operations in First Half of 2025, Marking a Significant Milestone Reaffirms 2025 Guidance for Net Income of ~$1.3 Million on Revenue of Over $45 Million; Projects 2026 Net Income of ~$5.0 Million on Revenue of More than $60 Million NEW YORK, NY, Aug. 15, 2025 (GLOBE NEWSWIRE) -- 1847 Holdings LLC ("1847" or the "Company") (Ticker: EFSH), a holding company specializing in identifying overlooked, deep-value

    8/15/25 1:30:00 PM ET
    $EFSH
    Professional Services
    Consumer Discretionary

    Perfect Moment Reports Strong Fiscal Q1 2026 Results

    51% year-over-year revenue growth and record gross margin of 60.4% Strong margin expansion driven by new revenue streams, enhanced channel mix, and disciplined cost management Perfect Moment Ltd. (NYSE:PMNT) ("Perfect Moment" or the "Company"), the high-performance, luxury skiwear and lifestyle brand that fuses technical excellence with fashion-led designs, reported results for its fiscal first quarter 2026 ended June 30, 2025. Financial Highlights Revenue up 51% to $1.5 million compared to $974,000 in Q1 FY25. Gross margin improved to a record 60.4%, up from 36.6% in Q1 FY25. Growth driven by the successful launch of new revenue streams, including collaboration and partnersh

    8/14/25 4:15:00 PM ET
    $PMNT
    Apparel
    Consumer Discretionary

    $ALLR
    $ATCH
    $ATIP
    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Commercial Officer Teh Ban Seng sold $261,376 worth of Ordinary Shares (1,724 units at $151.61) and exercised 1,724 units of Ordinary Shares at a strike of $69.89 (SEC Form 4)

    4 - Seagate Technology Holdings plc (0001137789) (Issuer)

    8/12/25 6:15:21 PM ET
    $STX
    Electronic Components
    Technology

    Director Geldmacher Jay L sold $376,250 worth of Ordinary Shares (2,500 units at $150.50), decreasing direct ownership by 88% to 352 units (SEC Form 4)

    4 - Seagate Technology Holdings plc (0001137789) (Issuer)

    8/7/25 4:14:11 PM ET
    $STX
    Electronic Components
    Technology

    President and CEO Paterson Dan sold $7,739 worth of shares (1,332 units at $5.81), decreasing direct ownership by 0.30% to 442,507 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    8/6/25 8:38:35 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $ATCH
    $ATIP
    $AZTR
    SEC Filings

    View All

    SEC Form EFFECT filed by Verastem Inc.

    EFFECT - Verastem, Inc. (0001526119) (Filer)

    8/18/25 12:15:32 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Wheels Up Experience Inc.

    144 - Wheels Up Experience Inc. (0001819516) (Subject)

    8/15/25 5:13:33 PM ET
    $UP
    Transportation Services
    Consumer Discretionary

    SEC Form 10-Q filed by Allarity Therapeutics Inc.

    10-Q - Allarity Therapeutics, Inc. (0001860657) (Filer)

    8/15/25 4:30:58 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $ATCH
    $ATIP
    $AZTR
    Leadership Updates

    Live Leadership Updates

    View All

    Volato Group's Proposed Acquisition Under Definitive Agreement, M2i Global Appoints Jon Najarian as a Senior Advisor

    Atlanta, GA and Reno, NV, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Volato Group, Inc. ("Volato") (NYSE:SOAR), a technology-driven private aviation company and M2i Global, Inc. ("M2i Global") (OTCQB:MTWO), a company specializing in the development and execution of a complete global value supply chain for critical minerals, is pleased to announce that Jon Najarian, a renowned market analyst and media personality, has joined M2i Global's Advisory Board. M2i's ecosystem provides partners with access to turnkey solutions, facilitating expanded business opportunities, securing offtake agreements, influencing strategic government policy, engaging with aligned NGOs, and trusted laboratories.  Major Gen

    8/12/25 9:00:00 AM ET
    $SOAR
    Transportation Services
    Consumer Discretionary

    Seagate Appoints Dave Mosley to Position of Board Chair

    Chief Executive Officer Dave Mosley elected to become Board Chair Michael R. Cannon to become Lead Independent Director Seagate Technology Holdings plc (NASDAQ:STX) (the "Company" or "Seagate"), a leading innovator of mass-capacity data storage, announced today that Chief Executive Officer Dave Mosley has been unanimously elected by the Board of Directors to the additional role of Board Chair, effective following the conclusion of Seagate's 2025 Annual General Meeting of Shareholders, which is expected to be held in October 2025. He will succeed Michael R. Cannon, who will remain a director and assume the additional role of Lead Independent Director. "Since becoming CEO in 2017, Da

    7/28/25 4:05:00 PM ET
    $STX
    Electronic Components
    Technology

    Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

        TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period. Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other

    7/7/25 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $ATCH
    $ATIP
    $AZTR
    Financials

    Live finance-specific insights

    View All

    Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

        - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. "The second quarter of 2025 marked a period

    8/15/25 4:30:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    1847 Holdings Reports 380% Revenue Growth to $12.8 Million in Q2 2025

    Gross Profit Rises 462% to $6.7 Million Net Income from Continuing Operations Improved by $26.6 Million to $23.7 Million Revenue for First Half of 2025 Increased 382% to $22.9 Million, a $18.1 Million Increase from Prior Year Generated $973,606 in Positive Cash Flow from Continuing Operations in First Half of 2025, Marking a Significant Milestone Reaffirms 2025 Guidance for Net Income of ~$1.3 Million on Revenue of Over $45 Million; Projects 2026 Net Income of ~$5.0 Million on Revenue of More than $60 Million NEW YORK, NY, Aug. 15, 2025 (GLOBE NEWSWIRE) -- 1847 Holdings LLC ("1847" or the "Company") (Ticker: EFSH), a holding company specializing in identifying overlooked, deep-value

    8/15/25 1:30:00 PM ET
    $EFSH
    Professional Services
    Consumer Discretionary

    Perfect Moment Reports Strong Fiscal Q1 2026 Results

    51% year-over-year revenue growth and record gross margin of 60.4% Strong margin expansion driven by new revenue streams, enhanced channel mix, and disciplined cost management Perfect Moment Ltd. (NYSE:PMNT) ("Perfect Moment" or the "Company"), the high-performance, luxury skiwear and lifestyle brand that fuses technical excellence with fashion-led designs, reported results for its fiscal first quarter 2026 ended June 30, 2025. Financial Highlights Revenue up 51% to $1.5 million compared to $974,000 in Q1 FY25. Gross margin improved to a record 60.4%, up from 36.6% in Q1 FY25. Growth driven by the successful launch of new revenue streams, including collaboration and partnersh

    8/14/25 4:15:00 PM ET
    $PMNT
    Apparel
    Consumer Discretionary

    $ALLR
    $ATCH
    $ATIP
    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/2/24 4:57:34 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care